Clinical Trial Update: Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating a meningococcal A,C,W-135,Y conjugate vaccine given as a single dose in healthy adults aged 18-25 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal A,C,W-135,Y conjugate vaccine (Meningococcal conjugate vaccine (serogroups A, C, W-135, Y))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED